European Journal of Rheumatology
Original Article

Genistein protects dermal fibrosis in bleomycin-induced experimental scleroderma


Department of Rheumatology, Fırat University Faculty of Medicine, Elazığ, Turkey


Department of Pathology, Fırat University Faculty of Medicine, Elazığ, Turkey


Department of Internal Medicine, Fırat University Faculty of Medicine, Elazığ, Turkey

Eur J Rheumatol 2015; 2: 99-102
DOI: 10.5152/eurjrheum.2015.0110
Read: 2060 Downloads: 1106 Published: 03 September 2019


Objective: Genistein, a phytoestrogen, has anti-oxidant, anti-inflammatory, and anti-angiogenic properties. The aim of the present study is to evaluate the protective effect of genistein in bleomycin (BLM)-induced dermal fibrosis.


Material and Methods: This study involved four groups of Balb/c mice (n=10 per group). Mice in three groups were administered BLM [100 μg/day in 100 μL phosphate-buffered saline (PBS)] subcutaneously for 4 weeks; the remaining (control) group received only 100 μL/day of PBS subcutaneously. PBS or BLM was injected into the shaved upper back. Two of the BLM-treated groups also received genistein (1 or 3 mg/kg/day, subcutaneously, to the dorsal front of neck). At the end of the fourth week, all mice were sacrificed and blood and tissue samples were obtained.


Results: The BLM applications increased the dermal thicknesses, tissue hydroxyproline contents, α-smooth muscle actin-positive cell counts, and led to histopathologically prominent dermal fibrosis. The genistein treatments decreased the tissue hydroxyproline contents and dermal thicknesses, in the BLM-injected mice.


Conclusion: Genistein has antifibrotic potential in BLM-induced dermal fibrosis model. However, its therapeutic potentials on human scleroderma require evaluation in future studies.

EISSN 2148-4279